Unveiling Details, Unlocking Hope
Comprehensive Genomic & Transcriptomic Profiling with Ultra-sensitive ctDNA-MRD Monitoring
DNA
Genomic profiling of 504 genes with backbone-enhanced design
RNA
Transcriptomic profiling mRNA-seq of 19,435 genes
ctDNA-MRD Monitoring
Personalized 10 mutations, Fixed panel of 700 hotspots, Viral DNA with AI-enhanced
Informed Decision-making with Comprehensive Tumor Profiling
K-4CARE integrates cutting-edge genomic and transcriptomic profiling with AI-enhanced ctDNA-MRD monitoring, empowering clinicians to deliver personalized cancer care. Our platform aligns with guidelines from leading organizations, including: the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and U.S. Food and Drug Administration (FDA).
By integrating DNA, RNA, and ctDNA insights, K-4CARE delivers:
- Comprehensive biomarker coverage for diagnosis, prognosis, and therapy selection.
- Enhanced detection of rare structural variants and fusion events.
- Boosts detection sensitivity by 25% for both common and rare fusion variants.
- Utilizes a machine-learning model to predict tumor origin in Cancer of Unknown Primary (CUP), enabling site-specific therapy.
This approach provides a comprehensive molecular landscape of the tumor, facilitating informed clinical decision-making and ultimately improving patient outcomes.
Ultra-Sensitive ctDNA-MRD Monitoring: Track Treatment Response and Detect Recurrence Early
How do you know if the chosen treatment is working? K-4CARE provides ultra-sensitive ctDNA-MRD monitoring to track a patient's personalized profile, enabling:
- Treatment Response Monitoring: Real-time assessment of therapy effectiveness.
- Early Recurrence Detection: Sensitive detection of Minimal Residual Disease (MRD) for timely intervention.
- Tumor Evolution Tracking: Monitoring of tumor changes and the emergence of resistance mutations.
Following the initial K-4CARE test, ctDNA-MRD follow-up testing (K-4CARE n) is a cost-effective option, requiring only a blood sample and tailored to the patient's unique tumor profile.
Benefit of Comprehensive Genomic-Transcriptomic Profiling
1. Benefit of Comprehensive Genomic-Transcriptomic Profiling
Identify genetic alterations to guide targeted therapy (FDA-approved or investigated in clinical trials) for pan-cancer
2. MSI, TMB, PD-L1*
Predictive biomarkers of tumor response to immune-checkpoint inhibitors for pan-cancer
3. Homologous Recombination Deficiency (HRD)
Predictive biomarker of tumor response to PARP inhibitors and platinum-based chemotherapy for selected cancers
4. Germline Mutations and Biallelic Inactivation
Identify inherited cancer predispositions and guide personalized therapy for selected cancers. Confirm whether both alleles are inactivated in the tumor for prognosis and risk stratification.
5. Tumor Tissue of Origin for CUP
Identify the tumor tissue of origin for Cancer of Unknown Primary (CUP) to enable site-specific therapy
6. Oncovirus Profile (Viral DNA)
Detect viral DNA (HPV, EBV, HBV) linked to selected cancers, which can influence diagnosis, prognosis, and treatment choices
Why K-4CARE
Sequence Both DNA (504 genes + sWGS) + mRNA (19,435 genes)
Integrated Profiling: Tissue and Liquid Biopsies
All-in-One Testing
Integrated ctDNA-MRD Monitoring
Sample collection
Tissue sample
Block FFPE/FFPE tumor tissue slices (minimum tumor cell content of 30%)
